Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis-Reference-Cited by-同舟云学术

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

Published:2018-03-25 Issue:5 Volume:100 Page:494-501
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Pick Marjorie¹,Vainstein Vladimir¹,Goldschmidt Neta¹,Lavie David¹,Libster Diana¹,Gural Alexander¹,Grisariu Sigal¹,Avni Batia¹,Ben Yehuda Dina¹,Gatt Moshe E.¹^ORCID

Affiliation:

1. Department of Hematology; Hadassah Hebrew University Medical Center; Jerusalem Israel

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.13046/fullpdf

Reference34 articles.

1. Light chain amyloidosis 2012: a new era;Gatt;Br J Haematol,2013

2. What is new in diagnosis and management of light chain amyloidosis?;Palladini;Blood,2016

3. Multiple myeloma;Palumbo;N Engl J Med,2011

4. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies;Kumar;Hematology Am Soc Hematol Educ Program,2017

5. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management;Rajkumar;Am J Hematol,2016

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population;Oncology and Therapy;2024-08-04

2. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance;European Journal of Medicinal Chemistry;2024-05

3. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study;Annals of Hematology;2024-03-16

4. Advances in the Treatment of Extramedullary Multiple Myeloma;Journal of Clinical Personalized Medicine;2024

5. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice;Clinical Lymphoma Myeloma and Leukemia;2023-11